// App-Quantinova.ai

4822 : Combination efficacy of the selective HDAC inhibitor ACY-241 and paclitaxel in solid tumor models

Researchers

Presenter

  • Pengyu Huang

Principal Investigators

  • Ingrid Almeciga-Pinto

  • Min Yang

  • Simon S. Jones

  • Steven N. Quayle

Medical Centers

  • Acetylon Pharmaceuticals, Inc.3, Boston, MA

Locations

  • United States

Companies

  • Acetylon Pharmaceuti

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • ricolinostat

  • Paclitaxel

  • ACY1215

  • taxane

  • ACY-241

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved